Effect of Arbidol in treatment of COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19.Coronavirus infection, unspecifiedU07.1
- Registration Number
- IRCT20180725040596N2
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Age equal or greater than 18 years
Signing informed consent
Diagnosis of COVID-19 by chest CT-scan or RT-PCR test
Exclusion Criteria
Respiratory failure
People with a history of allergies to this drug and or a history of severe allergies
Patients who used Arbidol (Tablets, capsules, granules) before hospitalization
Women who are breastfeeding or pregnant
Renal or liver function failure
Anemia or thrombocytopenia
Patient who received immunosuppressive drug during 3 months ago
Congenital heart failure
History of arrhythmia
coagulation disorders
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method